RESEARCH TRIANGLE PARK, N.C., Sept. 13, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that it has agreed to sell approximately 2.6 million shares of its common stock at a price of $3.85 per share in a registered direct offering. The offering will raise gross proceeds to Tranzyme of approximately $10.0 million before deducting underwriters' discounts and other offering expenses. Tranzyme has also granted the underwriters a 30-day option to purchase up to an additional fifteen percent of the shares of common stock offered to cover over-allotments, if any, which would result in additional gross proceeds of approximately $1.5 million if exercised in full.
Tranzyme Pharma Raises $10 Million In Registered Direct Offering
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.